Serveur d'exploration sur Pittsburgh

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Treatment Goals of Pulmonary Hypertension

Identifieur interne : 000428 ( France/Analysis ); précédent : 000427; suivant : 000429

Treatment Goals of Pulmonary Hypertension

Auteurs : Vallerie V. Mclaughlin [États-Unis] ; Sean Patrick Gaine [Irlande (pays)] ; Luke S. Howard [Royaume-Uni] ; Hanno H. Leuchte [Allemagne] ; Michael A. Mathier [États-Unis] ; Sanjay Mehta [Canada] ; Massimillano Palazzini [Italie] ; Myung H. Park [États-Unis] ; Victor F. Tapson [États-Unis] ; Olivier Sitbon [France]

Source :

RBID : Pascal:14-0036897

Descripteurs français

English descriptors

Abstract

With significant therapeutic advances in the field of pulmonary arterial hypertension, the need to identify clinically relevant treatment goals that correlate with long-term outcome has emerged as 1 of the most critical tasks. Current goals include achieving modified New York Heart Association functional class I or II, 6-min walk distance >380 m, normalization of right ventricular size and function on echocardiograph, a decreasing or normalization of B-type natriuretic peptide (BNP), and hemodynamics with right atrial pressure <8 mm Hg and cardiac index >2.5 mg/kg/ min2. However, to more effectively prognosticate in the current era of complex treatments, it is becoming clear that the "bar" needs to be set higher, with more robust and clearer delineations aimed at parameters that correlate with long-term outcome; namely, exercise capacity and right heart function. Specifically, tests that accurately and noninvasively determine right ventricular function, such as cardiac magnetic resonance imaging and BNP/N-terminal pro-B-type natriuretic peptide, are emerging as promising indicators to serve as baseline predictors and treatment targets. Furthermore, studies focusing on outcomes have shown that no single test can reliably serve as a long-term prognostic marker and that composite treatment goals are more predictive of long-term outcome. It has been proposed that treatment goals be revised to include the following: modified New York Heart Association functional class I or II, 6-min walk distance ≥380 to 440 m, cardiopulmonary exercise test-measured peak oxygen consumption >15 ml/min/kg and ventilatory equivalent for carbon dioxide <45 l/min/l/min, BNP level toward "normal," echocardiograph and/or cardiac magnetic resonance imaging demonstrating normal/near-normal right ventricular size and function, and hemodynamics showing normalization of right ventricular function with right atrial pressure <8 mm Hg and cardiac index >2.5 to 3.0 l/min/m2.


Affiliations:


Links toward previous steps (curation, corpus...)


Links to Exploration step

Pascal:14-0036897

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Treatment Goals of Pulmonary Hypertension</title>
<author>
<name sortKey="Mclaughlin, Vallerie V" sort="Mclaughlin, Vallerie V" uniqKey="Mclaughlin V" first="Vallerie V." last="Mclaughlin">Vallerie V. Mclaughlin</name>
<affiliation wicri:level="2">
<inist:fA14 i1="01">
<s1>Division of Cardiovascular Medicine, University of Michigan Health System</s1>
<s2>Ann Arbor, Michigan</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Gaine, Sean Patrick" sort="Gaine, Sean Patrick" uniqKey="Gaine S" first="Sean Patrick" last="Gaine">Sean Patrick Gaine</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Pulmonology, Mater Misericordiae University Hospital</s1>
<s2>Dublin</s2>
<s3>IRL</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Irlande (pays)</country>
<wicri:noRegion>Dublin</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Howard, Luke S" sort="Howard, Luke S" uniqKey="Howard L" first="Luke S." last="Howard">Luke S. Howard</name>
<affiliation wicri:level="3">
<inist:fA14 i1="03">
<s1>National Heart and Lung Institute, National Pulmonary Hypertension Service, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Leuchte, Hanno H" sort="Leuchte, Hanno H" uniqKey="Leuchte H" first="Hanno H." last="Leuchte">Hanno H. Leuchte</name>
<affiliation wicri:level="4">
<inist:fA14 i1="04">
<s1>Division of Pulmonary Diseases, Ludwig-Maximilians-University, Klinikum Grosshadern</s1>
<s2>Munich</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName>
<region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
<settlement type="city">Munich</settlement>
</placeName>
<orgName type="university">Université Louis-et-Maximilien de Munich</orgName>
</affiliation>
</author>
<author>
<name sortKey="Mathier, Michael A" sort="Mathier, Michael A" uniqKey="Mathier M" first="Michael A." last="Mathier">Michael A. Mathier</name>
<affiliation wicri:level="2">
<inist:fA14 i1="05">
<s1>Pulmonary Hypertension Program, Heart and Vascular Institute, University of Pittsburgh Medical Center</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Mehta, Sanjay" sort="Mehta, Sanjay" uniqKey="Mehta S" first="Sanjay" last="Mehta">Sanjay Mehta</name>
<affiliation wicri:level="1">
<inist:fA14 i1="06">
<s1>Division of Respirology, London Health Sciences Centre-Victoria Hospital, Western University</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>London, Ontario</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Palazzini, Massimillano" sort="Palazzini, Massimillano" uniqKey="Palazzini M" first="Massimillano" last="Palazzini">Massimillano Palazzini</name>
<affiliation wicri:level="1">
<inist:fA14 i1="07">
<s1>Department of Experimental, Diagnostic, and Specialty Medicine, Bologna University Hospital</s1>
<s2>Bologna</s2>
<s3>ITA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Bologna</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Park, Myung H" sort="Park, Myung H" uniqKey="Park M" first="Myung H." last="Park">Myung H. Park</name>
<affiliation wicri:level="2">
<inist:fA14 i1="08">
<s1>University of Maryland School of Medicine, Division of Cardiology</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Tapson, Victor F" sort="Tapson, Victor F" uniqKey="Tapson V" first="Victor F." last="Tapson">Victor F. Tapson</name>
<affiliation wicri:level="2">
<inist:fA14 i1="09">
<s1>Duke University Medical Center</s1>
<s2>Durham, North Carolina</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Sitbon, Olivier" sort="Sitbon, Olivier" uniqKey="Sitbon O" first="Olivier" last="Sitbon">Olivier Sitbon</name>
<affiliation wicri:level="4">
<inist:fA14 i1="10">
<s1>Université Paris-Sud, AP-HP, CHU de Bicêtre, INSERM U999</s1>
<s2>Le Kremlin-Bicêtre</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion>
<wicri:noRegion>INSERM U999</wicri:noRegion>
<wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion>
<orgName type="university">Université Paris-Sud</orgName>
<placeName>
<settlement type="city">Orsay</settlement>
<region type="region" nuts="2">Île-de-France</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">14-0036897</idno>
<date when="2013">2013</date>
<idno type="stanalyst">PASCAL 14-0036897 INIST</idno>
<idno type="RBID">Pascal:14-0036897</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001043</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003559</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000F45</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000F45</idno>
<idno type="wicri:doubleKey">0735-1097:2013:Mclaughlin V:treatment:goals:of</idno>
<idno type="wicri:Area/Main/Merge">006766</idno>
<idno type="wicri:Area/Main/Curation">006411</idno>
<idno type="wicri:Area/Main/Exploration">006411</idno>
<idno type="wicri:Area/France/Extraction">000428</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Treatment Goals of Pulmonary Hypertension</title>
<author>
<name sortKey="Mclaughlin, Vallerie V" sort="Mclaughlin, Vallerie V" uniqKey="Mclaughlin V" first="Vallerie V." last="Mclaughlin">Vallerie V. Mclaughlin</name>
<affiliation wicri:level="2">
<inist:fA14 i1="01">
<s1>Division of Cardiovascular Medicine, University of Michigan Health System</s1>
<s2>Ann Arbor, Michigan</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Gaine, Sean Patrick" sort="Gaine, Sean Patrick" uniqKey="Gaine S" first="Sean Patrick" last="Gaine">Sean Patrick Gaine</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Pulmonology, Mater Misericordiae University Hospital</s1>
<s2>Dublin</s2>
<s3>IRL</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Irlande (pays)</country>
<wicri:noRegion>Dublin</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Howard, Luke S" sort="Howard, Luke S" uniqKey="Howard L" first="Luke S." last="Howard">Luke S. Howard</name>
<affiliation wicri:level="3">
<inist:fA14 i1="03">
<s1>National Heart and Lung Institute, National Pulmonary Hypertension Service, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Leuchte, Hanno H" sort="Leuchte, Hanno H" uniqKey="Leuchte H" first="Hanno H." last="Leuchte">Hanno H. Leuchte</name>
<affiliation wicri:level="4">
<inist:fA14 i1="04">
<s1>Division of Pulmonary Diseases, Ludwig-Maximilians-University, Klinikum Grosshadern</s1>
<s2>Munich</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName>
<region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
<settlement type="city">Munich</settlement>
</placeName>
<orgName type="university">Université Louis-et-Maximilien de Munich</orgName>
</affiliation>
</author>
<author>
<name sortKey="Mathier, Michael A" sort="Mathier, Michael A" uniqKey="Mathier M" first="Michael A." last="Mathier">Michael A. Mathier</name>
<affiliation wicri:level="2">
<inist:fA14 i1="05">
<s1>Pulmonary Hypertension Program, Heart and Vascular Institute, University of Pittsburgh Medical Center</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Mehta, Sanjay" sort="Mehta, Sanjay" uniqKey="Mehta S" first="Sanjay" last="Mehta">Sanjay Mehta</name>
<affiliation wicri:level="1">
<inist:fA14 i1="06">
<s1>Division of Respirology, London Health Sciences Centre-Victoria Hospital, Western University</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>London, Ontario</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Palazzini, Massimillano" sort="Palazzini, Massimillano" uniqKey="Palazzini M" first="Massimillano" last="Palazzini">Massimillano Palazzini</name>
<affiliation wicri:level="1">
<inist:fA14 i1="07">
<s1>Department of Experimental, Diagnostic, and Specialty Medicine, Bologna University Hospital</s1>
<s2>Bologna</s2>
<s3>ITA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Bologna</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Park, Myung H" sort="Park, Myung H" uniqKey="Park M" first="Myung H." last="Park">Myung H. Park</name>
<affiliation wicri:level="2">
<inist:fA14 i1="08">
<s1>University of Maryland School of Medicine, Division of Cardiology</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Tapson, Victor F" sort="Tapson, Victor F" uniqKey="Tapson V" first="Victor F." last="Tapson">Victor F. Tapson</name>
<affiliation wicri:level="2">
<inist:fA14 i1="09">
<s1>Duke University Medical Center</s1>
<s2>Durham, North Carolina</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Sitbon, Olivier" sort="Sitbon, Olivier" uniqKey="Sitbon O" first="Olivier" last="Sitbon">Olivier Sitbon</name>
<affiliation wicri:level="4">
<inist:fA14 i1="10">
<s1>Université Paris-Sud, AP-HP, CHU de Bicêtre, INSERM U999</s1>
<s2>Le Kremlin-Bicêtre</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion>
<wicri:noRegion>INSERM U999</wicri:noRegion>
<wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion>
<orgName type="university">Université Paris-Sud</orgName>
<placeName>
<settlement type="city">Orsay</settlement>
<region type="region" nuts="2">Île-de-France</region>
</placeName>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Journal of the American College of Cardiology</title>
<title level="j" type="abbreviated">J. Am. Coll. Cardiol.</title>
<idno type="ISSN">0735-1097</idno>
<imprint>
<date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Journal of the American College of Cardiology</title>
<title level="j" type="abbreviated">J. Am. Coll. Cardiol.</title>
<idno type="ISSN">0735-1097</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Cardiology</term>
<term>Cardiovascular disease</term>
<term>Circulatory system</term>
<term>Goal</term>
<term>Pulmonary hypertension</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Hypertension artérielle pulmonaire</term>
<term>Pathologie de l'appareil circulatoire</term>
<term>Traitement</term>
<term>But</term>
<term>Appareil circulatoire</term>
<term>Cardiologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">With significant therapeutic advances in the field of pulmonary arterial hypertension, the need to identify clinically relevant treatment goals that correlate with long-term outcome has emerged as 1 of the most critical tasks. Current goals include achieving modified New York Heart Association functional class I or II, 6-min walk distance >380 m, normalization of right ventricular size and function on echocardiograph, a decreasing or normalization of B-type natriuretic peptide (BNP), and hemodynamics with right atrial pressure <8 mm Hg and cardiac index >2.5 mg/kg/ min
<sup>2</sup>
. However, to more effectively prognosticate in the current era of complex treatments, it is becoming clear that the "bar" needs to be set higher, with more robust and clearer delineations aimed at parameters that correlate with long-term outcome; namely, exercise capacity and right heart function. Specifically, tests that accurately and noninvasively determine right ventricular function, such as cardiac magnetic resonance imaging and BNP/N-terminal pro-B-type natriuretic peptide, are emerging as promising indicators to serve as baseline predictors and treatment targets. Furthermore, studies focusing on outcomes have shown that no single test can reliably serve as a long-term prognostic marker and that composite treatment goals are more predictive of long-term outcome. It has been proposed that treatment goals be revised to include the following: modified New York Heart Association functional class I or II, 6-min walk distance ≥380 to 440 m, cardiopulmonary exercise test-measured peak oxygen consumption >15 ml/min/kg and ventilatory equivalent for carbon dioxide <45 l/min/l/min, BNP level toward "normal," echocardiograph and/or cardiac magnetic resonance imaging demonstrating normal/near-normal right ventricular size and function, and hemodynamics showing normalization of right ventricular function with right atrial pressure <8 mm Hg and cardiac index >2.5 to 3.0 l/min/m
<sup>2</sup>
.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Allemagne</li>
<li>Canada</li>
<li>France</li>
<li>Irlande (pays)</li>
<li>Italie</li>
<li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region>
<li>Angleterre</li>
<li>Bavière</li>
<li>Caroline du Nord</li>
<li>District de Haute-Bavière</li>
<li>Grand Londres</li>
<li>Maryland</li>
<li>Michigan</li>
<li>Pennsylvanie</li>
<li>Île-de-France</li>
</region>
<settlement>
<li>Londres</li>
<li>Munich</li>
<li>Orsay</li>
</settlement>
<orgName>
<li>Université Louis-et-Maximilien de Munich</li>
<li>Université Paris-Sud</li>
</orgName>
</list>
<tree>
<country name="États-Unis">
<region name="Michigan">
<name sortKey="Mclaughlin, Vallerie V" sort="Mclaughlin, Vallerie V" uniqKey="Mclaughlin V" first="Vallerie V." last="Mclaughlin">Vallerie V. Mclaughlin</name>
</region>
<name sortKey="Mathier, Michael A" sort="Mathier, Michael A" uniqKey="Mathier M" first="Michael A." last="Mathier">Michael A. Mathier</name>
<name sortKey="Park, Myung H" sort="Park, Myung H" uniqKey="Park M" first="Myung H." last="Park">Myung H. Park</name>
<name sortKey="Tapson, Victor F" sort="Tapson, Victor F" uniqKey="Tapson V" first="Victor F." last="Tapson">Victor F. Tapson</name>
</country>
<country name="Irlande (pays)">
<noRegion>
<name sortKey="Gaine, Sean Patrick" sort="Gaine, Sean Patrick" uniqKey="Gaine S" first="Sean Patrick" last="Gaine">Sean Patrick Gaine</name>
</noRegion>
</country>
<country name="Royaume-Uni">
<region name="Angleterre">
<name sortKey="Howard, Luke S" sort="Howard, Luke S" uniqKey="Howard L" first="Luke S." last="Howard">Luke S. Howard</name>
</region>
</country>
<country name="Allemagne">
<region name="Bavière">
<name sortKey="Leuchte, Hanno H" sort="Leuchte, Hanno H" uniqKey="Leuchte H" first="Hanno H." last="Leuchte">Hanno H. Leuchte</name>
</region>
</country>
<country name="Canada">
<noRegion>
<name sortKey="Mehta, Sanjay" sort="Mehta, Sanjay" uniqKey="Mehta S" first="Sanjay" last="Mehta">Sanjay Mehta</name>
</noRegion>
</country>
<country name="Italie">
<noRegion>
<name sortKey="Palazzini, Massimillano" sort="Palazzini, Massimillano" uniqKey="Palazzini M" first="Massimillano" last="Palazzini">Massimillano Palazzini</name>
</noRegion>
</country>
<country name="France">
<region name="Île-de-France">
<name sortKey="Sitbon, Olivier" sort="Sitbon, Olivier" uniqKey="Sitbon O" first="Olivier" last="Sitbon">Olivier Sitbon</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000428 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000428 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Amérique
   |area=    PittsburghV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     Pascal:14-0036897
   |texte=   Treatment Goals of Pulmonary Hypertension
}}

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021